Comparing the current results to its competitors, Qhslab Inc reported Revenue increase in the 2 quarter 2026 by 39.98 % year on year. The sales growth was above Qhslab Inc 's competitors' average revenue growth of 9.39 %, achieved in the same quarter.
Qhslab Inc 's Comment on Competition and Industry Peers
The company operates in the healthcare technology and medical device sectors, competing with point-solution digital health vendors specializing in single conditions, behavioral health screening and care management platforms, chronic care management software providers, EHR-embedded tools and third-party add-ons, as well as allergy diagnostic device manufacturers and specialty-focused providers. Competitors in these markets often possess greater financial, technical, or marketing resources. Competition in both the digital health and allergy diagnostics markets is intense.
Strong sales growth of 39.98 % in Overall company contributed to Qhslab Inc increase in total revenue by 39.98 % Qhslab Inc improved its market share in this segment, to approximately 0 %.
Euda Health Holdings Limited operates as a digital health platform that facilitates access to healthcare services. They offer a range of online health consultations and concierge services, enabling users to connect with healthcare professionals and receive personalized medical advice and treatment. Their business model focuses on leveraging technology to streamline the healthcare experience and improve access to quality care for individuals seeking medical assistance.
Lucid Diagnostics Inc is a healthcare company that operates with a business model focused on developing and providing innovative diagnostic solutions for the early detection and prevention of diseases, aimed at improving patient outcomes and reducing healthcare costs. They leverage advanced technologies and medical expertise to deliver accurate and reliable diagnostic services to healthcare providers, enabling better decision-making and personalized treatment plans for patients.
Genedx Holdings Corp operates as a genetic testing company, offering molecular and biochemical testing services for various genetic disorders and diseases. The company generates revenue by providing testing services to medical professionals and institutions around the world, aiding in accurate diagnosis and treatment planning for patients.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Qhslab Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Qhslab Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
